Reduced blood BDCA-2+ (lymphoid) and CD11c+ (myeloid) dendritic cells in systemic lupus erythematosus - PubMed (original) (raw)

Reduced blood BDCA-2+ (lymphoid) and CD11c+ (myeloid) dendritic cells in systemic lupus erythematosus

K Migita et al. Clin Exp Immunol. 2005 Oct.

Abstract

Type 1 IFN is thought to be implicated in the autoimmune process of SLE. Plasmacytoid dendric cells (DC), which are natural IFN-alpha producing cells, play a pivotal epipathogenic role in SLE. The present study was undertaken to investigate the phenotypic characteristics of peripheral blood DC in SLE patients in comparison with those of healthy controls. Samples from 20 SLE patients and 18 healthy controls were studied. Three-colour flow cytometry was performed to identify myeloid DC, as CD11c(+) lineage marker(-), and HLA-DR(+) cells and plasmacytoid DC, as BDCA-2(+) linage marker(-), and HLA-DR(+) cells. We used the whole blood 'lyse/no-wash' procedure, which allows precise counting of peripheral blood DC. BDCA-2(+) plasmacytoid DC and CD11c(+) myeloid DC were reduced in SLE patients compared with controls. Similarly, BDCA-3(+) DC were reduced in SLE patients. These results indicated that SLE patients had a reduced number of both BDCA-2(+) plasmacytoid DC and CD11c(+) myeloid DC. These alternations of the DC subset may drive the autoimmune response in SLE.

PubMed Disclaimer

Figures

Fig. 1

Gating strategy used to define BDCA-2+ and CD11c+ DCs by flowcytometry. Peripheral blood mononuclear cells were selected in the R1 gate excluding debris and polynuclear cells (a). Lineage-negative and HLA-DR-positive cells were selected in the R2 gate (b). In this combined R1 and R2 gate, CD11c+, HLA-DR+ (c)(R3) or BDCA-2+, HLA-DR+ (d)(R3) events were quantified.

Fig. 2

(a) Blood BDCA-2+ DC percentage in SLE patients and healthy controls. Percentages of BDCA-2+ DC were analysed by flow cytometry as shown in Fig. 1. Boxes show the 25th and 75th percentiles. Horizontal lines within the boxes show the median. Bars above and below the boxes show the 10th and 90th percentiles. Significance levels for differences between groups were analysed by the Mann–Whitney _U_-test. (b) Blood BDCA-2+ DC absolute numbers in SLE patients and healthy controls. Absolute numbers of BDCA-2+ DC were calculated using the percentage of BDCA-2+ DC and the mononuclear cell count determined by the automated haematology blood analysis. Boxes show the 25th and 75th percentiles. Horizontal lines within the boxes show the median. Bars above and below the boxes show the 10th and 90th percentiles. Significance levels for differences between groups were analysed by the Mann–Whitney _U_-test.

Fig. 3

(a) Blood CD11c+ DC percentage in SLE patients and healthy controls. Percentages of CD11c+ DC were analysed by flow cytometry as shown in Fig. 1. Boxes show the 25th and 75th percentiles. Horizontal lines within the boxes show the median. Bars above and below the boxes show the 10th and 90th percentiles. Significance levels for differences between groups were analysed by the Mann–Whitney _U_-test. (b) Blood CD11c+ DC absolute numbers in SLE patients and healthy controls. Absolute numbers of CD11c+ DC were calculated using the percentage of CD11c+ DC and the mononuclear cell count determined by the automated haematology blood analysis. Boxes show the 25th and 75th percentiles. Horizontal lines within the boxes show the median. Bars above and below the boxes show the 10th and 90th percentiles. Significance levels for differences between groups were analysed by the Mann–Whitney _U_-test.

Fig. 4

(a) Blood BDCA-3+ DC percentage in SLE patients and healthy controls. Percentages of BDCA-3+ DC were analysed by flow cytometry as shown in Fig. 1. Boxes show the 25th and 75th percentiles. Horizontal lines within the boxes show the median. Bars above and below the boxes show the 10th and 90th percentiles. Significance levels for differences between groups were analysed by the Mann–Whitney _U_-test. (b) Blood BDCA-3+ DC absolute numbers in SLE patients and healthy controls. Absolute numbers of BDCA-3+ DC were calculated using the percentage of BDCA-3+ DC and the mononuclear cell count determined by the automated haematology blood analysis. Boxes show the 25th and 75th percentiles. Horizontal lines within the boxes show the median. Bars above and below the boxes show the 10th and 90th percentiles. Significance levels for differences between groups were analysed by the Mann–Whitney _U_-test.

Fig. 5

Blood DC percentages in RA patients and healthy controls.Percentages of (a) BDCA-2+, (b) CD11c+ and (c) BDCA-3+ DC were analysed by flow cytometry as shown in Fig. 1. Boxes show the 25th and 75th percentiles. Horizontal lines within the boxes show the median. Bars above and below the boxes show the 10th and 90th percentiles. Significance levels for differences between groups were analysed by the Mann–Whitney _U_-test.

Fig. 6

(a) The CD11c+: BDCA-2+ DC ratio in SLE patients (n = 20) and healthy controls (n = 18). (b) The BDCA-3+: BDCA-2+ DC ratio in SLE patients (n = 20) and healthy controls (n = 18).

Fig. 7

(a) Correlation between BDCA-2+ DC and peripheral blood lymphocyte counts. The percentages of BDCA-2+ DC were determined by flow cytometry. Peripheral blood lymphocyte counts were determined by the automated haematology blood analysis. (b) Correlation between BDCA-2+ plus CD11c+ DC and peripheral blood lymphocyte counts. (c) Correlation between CD11c+ DC and peripheral blood lymphocyte counts. (d) Correlation between BDCA-3+ DC and peripheral blood lymphocyte counts.

Similar articles

• Expression of dendritic cell markers CD11c/BDCA-1 and CD123/BDCA-2 in coronary artery disease upon activation in whole blood.
  Van Brussel I, Van Vré EA, De Meyer GR, Vrints CJ, Bosmans JM, Bult H. Van Brussel I, et al. J Immunol Methods. 2010 Oct 31;362(1-2):168-75. doi: 10.1016/j.jim.2010.09.031. Epub 2010 Oct 1. J Immunol Methods. 2010. PMID: 20888334 Clinical Trial.
• Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus.
  Blomberg S, Eloranta ML, Magnusson M, Alm GV, Rönnblom L. Blomberg S, et al. Arthritis Rheum. 2003 Sep;48(9):2524-32. doi: 10.1002/art.11225. Arthritis Rheum. 2003. PMID: 13130472
• Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies.
  Scheinecker C, Zwölfer B, Köller M, Männer G, Smolen JS. Scheinecker C, et al. Arthritis Rheum. 2001 Apr;44(4):856-65. doi: 10.1002/1529-0131(200104)44:4<856::AID-ANR142>3.0.CO;2-A. Arthritis Rheum. 2001. PMID: 11315925
• Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus.
  Chan VS, Nie YJ, Shen N, Yan S, Mok MY, Lau CS. Chan VS, et al. Autoimmun Rev. 2012 Oct;11(12):890-7. doi: 10.1016/j.autrev.2012.03.004. Epub 2012 Mar 20. Autoimmun Rev. 2012. PMID: 22503660 Review.
• The role myeloid dendritic cells play in the pathogenesis of systemic lupus erythematosus.
  Crispin JC, Alcocer-Varela J. Crispin JC, et al. Autoimmun Rev. 2007 Aug;6(7):450-6. doi: 10.1016/j.autrev.2007.01.014. Epub 2007 Feb 23. Autoimmun Rev. 2007. PMID: 17643932 Review.

Cited by

• The role of immune cells in the pathogenesis of connective tissue diseases-associated pulmonary arterial hypertension.
  Li Z, Ma J, Wang X, Zhu L, Gan Y, Dai B. Li Z, et al. Front Immunol. 2024 Sep 17;15:1464762. doi: 10.3389/fimmu.2024.1464762. eCollection 2024. Front Immunol. 2024. PMID: 39355239 Free PMC article. Review.
• Integrin αvβ3 Limits Cytokine Production by Plasmacytoid Dendritic Cells and Restricts TLR-Driven Autoimmunity.
  Lorant AK, Yoshida AE, Gilbertson EA, Chu T, Stefani C, Acharya M, Hamerman JA, Lacy-Hulbert A. Lorant AK, et al. J Immunol. 2024 Jun 1;212(11):1680-1692. doi: 10.4049/jimmunol.2300290. J Immunol. 2024. PMID: 38607278
• CSL362 potently and specifically depletes pDCs in vitro and ablates SLE-immune complex-induced IFN responses.
  Monaghan KA, Hoi A, Gamell C, Tai TY, Linggi B, Jordan J, Cesaroni M, Sato T, Ng M, Oon S, Benson J, Wicks I, Morand E, Wilson N. Monaghan KA, et al. iScience. 2023 Jun 20;26(7):107173. doi: 10.1016/j.isci.2023.107173. eCollection 2023 Jul 21. iScience. 2023. PMID: 37456846 Free PMC article.
• Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy.
  Hawtin S, André C, Collignon-Zipfel G, Appenzeller S, Bannert B, Baumgartner L, Beck D, Betschart C, Boulay T, Brunner HI, Ceci M, Deane J, Feifel R, Ferrero E, Kyburz D, Lafossas F, Loetscher P, Merz-Stoeckle C, Michellys P, Nuesslein-Hildesheim B, Raulf F, Rush JS, Ruzzante G, Stein T, Zaharevitz S, Wieczorek G, Siegel R, Gergely P, Shisha T, Junt T. Hawtin S, et al. Cell Rep Med. 2023 May 16;4(5):101036. doi: 10.1016/j.xcrm.2023.101036. Cell Rep Med. 2023. PMID: 37196635 Free PMC article.
• Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
  Jachiet V, Ricard L, Hirsch P, Malard F, Pascal L, Beyne-Rauzy O, Peterlin P, Maria ATJ, Vey N, D'Aveni M, Gourin MP, Dimicoli-Salazar S, Banos A, Wickenhauser S, Terriou L, De Renzis B, Durot E, Natarajan-Ame S, Vekhoff A, Voillat L, Park S, Vinit J, Dieval C, Dellal A, Grobost V, Willems L, Rossignol J, Solary E, Kosmider O, Dulphy N, Zhao LP, Adès L, Fenaux P, Fain O, Mohty M, Gaugler B, Mekinian A; MINHEMON: French Network of dysimmune disorders associated with hemopathies. Jachiet V, et al. Clin Exp Med. 2023 Jul;23(3):803-813. doi: 10.1007/s10238-022-00866-5. Epub 2022 Aug 11. Clin Exp Med. 2023. PMID: 35953763

References

1. 1. Liossis SN, Vassilopoulos D, Kovacs B, Tsokos GC. Immune cell biochemical abnormalities in systemic lupus erythematosus. Clin Exp Rheumatol. 1997;15:677–84. - PubMed
2. 1. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet. 2001;357:1027–32. - PubMed
3. 1. Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 2001;22:427–31. - PubMed
4. 1. Ronnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med. 2001;194:59–63. - PMC - PubMed
5. 1. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982;25:401–6. - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems
  • Wiley

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program